#Japan #biopharmaceuticals #Tokyo #Fujifilm #HORIBA

Innovative Technology for Biopharmaceutical Production

In a remarkable collaboration, Fujifilm Corporation, based in Minato, Tokyo, and Horiba Ltd., located in Kyoto, have introduced an advanced inline Raman high-sensitivity measurement system. This innovative technology aims to continuously and visually represent the concentration of components within biopharmaceutical manufacturing processes, particularly in culture and purification steps. This initiative is set to enhance the efficiency and yield of antibody drugs considerably.

Enhancing Biopharmaceuticals

Biopharmaceuticals are drugs derived from biological sources, mainly proteins and antibodies, that treat various diseases including cancers and immune disorders. The global market for biopharmaceuticals is experiencing a robust growth rate of approximately 9% annually. The development and manufacturing processes of these therapeutics are critically sensitive to environmental conditions. Minor changes, such as oxygen concentration within the culture medium, can drastically impact product quality and yield.

Traditionally, the analysis of culture fluids has relied on offline methods, limiting the ability to monitor real-time variations. The need for real-time monitoring technologies has surged to achieve precision in analyzing these biological processes. The newly developed inline Raman measurement system addresses these needs, providing an opportunity for heightened efficiency in the manufacturing of biopharmaceuticals.

Features of the Inline Raman System

The inline Raman high-sensitivity measurement system integrates Horiba’s state-of-the-art Raman spectrometry with Fujifilm's unique single-use probes and sophisticated measurement algorithms. This combination allows for exceptional sensitivity and precision during analysis. The Raman spectrometer from Horiba has a proven track record in demanding environments, such as the oil industry, and boasts exceptional stability during extensive operations.

Fujifilm's optical expertise contributes to a probe that efficiently collects light, facilitating the detection of faint Raman signals that would have been challenging to measure previously. This innovation has led to the realization of industry-leading sensitivity, ensuring that adequate accuracy can be maintained even with brief measurement periods, thus enhancing throughput.

Moreover, Fujifilm’s proprietary measurement algorithm efficiently extracts characteristic peaks from the measured Raman spectra. This allows for high-precision temporal monitoring of concentration changes for biopharmaceuticals, enabling manufacturers to identify changes in product quality or yield precisely.

Application in Biopharmaceutical Production

The system's application has yielded notable results, particularly in the purification phases of antibody production. The traditional UV-Vis spectrometry methods could track total protein levels but struggled with distinguishing antibodies from similar impurities. With the new system, precise separation and concentration monitoring of antibodies and impurities are achievable, thus enhancing overall yield by around 10% compared to conventional methods. This potential for improvement suggests wide-ranging benefits not only for antibody production but also for other biopharmaceutical entities striving for higher quality and yields.

Looking Ahead

Fujifilm and Horiba are committed to further practical applications of this measurement system. As they progress with its implementation verification, they foresee significant contributions to stabilizing the production of high-quality biopharmaceuticals while reducing costs. Beyond the immediate benefits, the technology promises to expedite process development by minimizing downtime associated with offline sampling, fostering expedited validation processes.

As the biopharmaceutical sector continues to evolve, advancements such as the inline Raman measurement system signify a leap toward more efficient and reliable manufacturing processes. This collaboration exemplifies how harnessing advanced technology can meet the increasing demands of the healthcare market, reflecting a positive shift for both companies and patients alike.

Conclusion

Fujifilm and Horiba’s collaboration represents a pivotal advancement in biopharmaceutical manufacturing. Their innovative inline Raman measurement system not only enhances production efficiencies but also promises a future where biopharmaceuticals can be manufactured with even greater quality and yields, ultimately benefiting patients around the globe.